- CompletedNot Applicable
Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus
This UK study explores whether combining the diabetes tablet dapagliflozin with a tailored exercise programme helps people with type 2 diabetes move more easily and stay strong. Researchers want to see if this combination improves everyday physical fitness better than the medicine on its own or a healthy diet plan.
For: Diabetes mellitusUnited Kingdom · England - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
For: Type 2 Diabetes MellitusUnited States · Argentina · Brazil - AuthorisedPhase III and phase IV (Integrated)
SCARP-DIAL (SGLT2i for CARdiovascular Protection in DIALysis)
The SCARP-DIAL study is testing a daily tablet called dapagliflozin in people receiving long-term dialysis. Researchers want to find out if this medication can help protect the heart and lower the risk of heart attacks, strokes, and emergency hospital visits for heart problems in people with kidney failure.
For: Chronic dialysis, Cardiovascular diseaseSweden - RecruitingPHASE3
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
This study looks at a new combination medicine for people with long-term kidney disease (CKD stages 3b and 4). It compares a new drug (balcinrenone/dapagliflozin) with an existing one (dapagliflozin) to see if it can slow down kidney disease and reduce heart problems, while being safe.
For: Renal Insufficiency, ChronicUnited States · Argentina · Austria - Active not recruitingPHASE3
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
This study is looking into a new combination treatment (Zibotentan/Dapagliflozin) for chronic kidney disease with high protein levels in the urine. It compares this combination with an existing treatment (Dapagliflozin) to see if it's more effective and safe.
For: Chronic Kidney Disease With High ProteinuriaUnited States · Argentina · Australia - RecruitingPHASE3
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
This study looks at a new treatment called dapagliflozin for young people (aged 10-39) with Alport syndrome, a type of chronic kidney disease. It aims to see if this medicine can slow down kidney damage and improve their quality of life.
For: Chronic Kidney Failure in Children and Young AdultsGermany - Recruiting
DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
This study looks for better ways to measure how well kidneys work, especially in early kidney disease. It compares new tests with current methods to see how kidneys respond to stress, like after eating protein, aiming for earlier detection and better understanding of kidney health.
For: Chronic Kidney DiseasesUnited Kingdom - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
For: Immunoglobulin A NephropathyUnited States · Australia · Belgium